D-0723-2026 Class II Ongoing

Recalled by Lupin Pharmaceuticals Inc. — Naples, FL

FDA drug recall D-0723-2026 was initiated by Lupin Pharmaceuticals Inc. on Jun 23, 2026 and is designated Class II. Reason for recall: CGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing. The recall status is ongoing. Affected quantity: 64,894 units.

Recall details

Product Type
Drugs
Report Date
Jul 8, 2026
Initiation Date
Jun 23, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
64,894 units

Product description

Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection USP, 1mg per vial, Diluent for Glucagon, 1 mL syringe, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur - 441108, INDIA, NDC 70748-311-01

Reason for recall

CGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing.

Distribution pattern

Nationwide within the U.S.

Code information

Kit Lots: WB00010, Exp. Date Jan 2027; WB00017, WB00019, Exp. Date Feb 2027; WB00070, Exp. Date Jun 2027; WB00077, WB00078, Exp. Date Jul 2027; WB00130, Exp. Date Nov 2027.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0723-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0723-2026. Report a data issue: hello@regdatalab.com.